Stocks including Bharat Electronics, Gujarat Kidney, Grasim, Lupin, Waaree Energies, NTPC Green, Afcons Infra, Timex India and more will be in the spotlight on Tuesday, December 30.
Vinita Gupta, CEO at Lupin told Business Today that the company’s strategy is centred on high-barrier products, operational efficiency and selective expansion across key markets.
The path to the top is rarely smooth, but Lupin's Vinita Gupta says women leaders must lead with conviction and a global mindset
Stocks including ICICI Pru AMC, RIL, Airtel, HCL Tech, BPCL, Voda Idea, Lupin, IndiGo, Biocon, Bharti Hexacom, Swiggy and more will be in the spotlight on Friday, December 19.
Stocks including Nephrocare, Reliance, Park Medi, Akzo Nobel, Indian Overseas Bank, Vedanta, NBCC, Ola Electric, RVNL, Zaggle Prepaid and more will be in the spotlight on Wednesday, December 17.
Lupin has received USFDA approval for its biosimilar Armlupeg (pegfilgrastim-unne) injection, to be manufactured at its Pune facility.
The United States market remains the company’s strongest growth driver, contributing 40% of total sales and rising 47% year-on-year to ₹2,762 crore.
Stocks including Lenskart, Bajaj Auto, Hindustan Aeronautics, Trent, Nykaa, National Aluminium, Swiggy, Lupin, Anant Raj, Medanta and more will be in the spotlight on Monday, November 10.
Lupin reported a 24% year-on-year rise in Q2FY26 revenue to ₹6,831 crore, led by strong growth in the U.S. and emerging markets. EBITDA rose 76% to ₹2,431 crore with margins improving to 35.6%. Profit after tax stood at ₹1,485 crore, up 73% YoY. The company received six ANDA approvals and launched six new products in the U.S. Lupin remains the third-largest generic player in the U.S. and has turned net cash positive.
Stocks including Studds Accessories, Bharti Airtel, Maruti Suzuki, ABB India, TVS Motor Company, RVNL, Lupin, NHPC and more will be in the spotlight on Friday, November 07.
Aurobindo Pharma derives 89 per cent of its revenue from exports, with nearly half (49 per cent) from the US. Similarly, Biocon earns about 46 per cent of its revenue from the American market.
Promo | Episode 4 - India Today @ 50




